OpenArc Corporate Advisory’s Travere Therapeutics TVTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.21M Buy
37,521
+21
+0.1% +$1.28K 0.02% 253
2026
Q2
$2.13M Buy
37,500
+6,500
+21% +$288K 0.03% 255
2026
Q1
$921K Hold
31,000
– – 0.01% 334
2025
Q4
$1.18M Buy
+31,000
New +$1.01M 0.02% 282

Other funds holding TVTX

OpenArc Corporate Advisory's TVTX Position: Q3 2026 in Review

OpenArc Corporate Advisory increased its Travere Therapeutics (TVTX) stake by 0.06% in Q3 2026, buying an estimated $1.28K and bringing the position to 37,521 shares worth $2.21M. The position accounts for 0.02% of the portfolio, ranked #253.

OpenArc Corporate Advisory first reported a position in TVTX in Q4 2025 and has held it in 4 quarters since. 344 funds tracked by Wall St. Rank hold TVTX as of Q3 2026.

  • OpenArc Corporate Advisory held 37,521 shares of Travere Therapeutics worth $2.21M as of Q3 2026.
  • OpenArc Corporate Advisory bought 21 Travere Therapeutics shares in Q3 2026, an estimated $1.28K.
  • Travere Therapeutics made up 0.02% of OpenArc Corporate Advisory's portfolio in Q3 2026, its #253 holding.
  • OpenArc Corporate Advisory first reported a position in Travere Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • 344 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2026.

Based on OpenArc Corporate Advisory's 13F filing for Q3 2026, filed 21 Oct 2026.